Gadolinium-Associated Plaques

Gathings, Robert M.; Reddy, Raveena; Cruz, Daniel Santa; Brodell, Robert T.

doi:10.1001/jamadermatol.2014.2660

Cited by 41 publications

(25 citation statements)

References 13 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gathings et al [25] recently described histologic features similar to NSF in two patients with normal renal function after receiving gadodiamide (Omni scan ® ). The authors named i t as gadolinium-associated plaques.…”

Section: Non-neurologicalmentioning

confidence: 98%

“…The authors named i t as gadolinium-associated plaques. These plaques (sclerotic bodies) had initially been thought to be pathognomonic for NSF, but in the report by Gathings et al both patients had no NSF and only one had renal disease [25]. The patient who did not have renal disease received high doses of gadolinium, suggesting that similar histologic features may be present in patients without NSF.…”

Section: Non-neurologicalmentioning

confidence: 99%

See 1 more Smart Citation

Gadolinium toxicity and treatment

Ramalho

Jay

et al. 2016

Magnetic Resonance Imaging

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oGadolinium based contrast agents (GBCAs) play an important role in the diagnostic evaluation of many patients. The safety of these agents has been once again questioned after gadolinium deposits were observed and measured in brain and bone of patients with normal renal function. This retention of gadolinium in the human body has been termed "gadolinium storage condition". The long-term and cumulative effects of retained gadolinium in the brain and elsewhere are not as yet understood. Recently, patients who report that they suffer from chronic symptoms secondary to gadolinium exposure and retention created gadolinium-toxicity on-line support groups. Their self-reported symptoms have recently been published. Bone and joint complaints, and skin changes were two of the most common complaints. This condition has been termed "gadolinium deposition disease". In this review we will address gadolinium toxicity disorders, from acute adverse reactions to GBCAs to gadolinium deposition disease, with special emphasis on the latter, as it is the most recently described and least known.

show abstract

Section: Non-neurologicalmentioning

confidence: 98%

Section: Non-neurologicalmentioning

confidence: 99%

Gadolinium toxicity and treatment

Ramalho

Jay

et al. 2016

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…It is reported that the renal dysfunction lengthens the residence time of the paramagnetic Gd chelates inside the organism during which Gd-CAs probably undergo metabolic reactions, such as transmetallation and binding to endogenous compounds. Nonetheless, high level of Gd retention and NSF-like symptoms, such as hardening and swelling of the skin along with pain in different parts of the body, were experienced by some patients with normal renal function who underwent several MRI examinations [182][183][184][185][186][187]. The hypothesis is that Gd precipitates along with calcium phosphate and forms persistent insoluble deposits with diameters of a few micrometers, triggering the circulation of fibrocytes, which subsequently initiate fibrosis [188].…”

Section: Human Health Risks Of Gd Anthmentioning

confidence: 99%

Gadolinium as an Emerging Microcontaminant in Water Resources: Threats and Opportunities

Ebrahimi

Barbieri

2019

Geosciences

View full text Add to dashboard Cite

As a result of high doses of paramagnetic gadolinium (Gd) chelates administered in magnetic resonance imaging (MRI) exams, their unmetabolized excretion, and insufficient removal in wastewater treatment plants (WWTPs), large amounts of anthropogenic Gd (Gdanth) are released into surface water. The upward trend of gadolinium-based contrast agent (Gd-CA) administrations is expected to continue growing and consequently higher and higher anthropogenic Gd concentrations are annually recorded in water resources, which can pose a great threat to aquatic organisms and human beings. In addition, the feasibility of Gd retention in patients administered with Gd-CAs repeatedly, and even potentially fatal diseases, including nephrogenic systemic fibrosis (NSF), due to trace amounts of Gd have recently arisen severe health concerns. Thus, there is a need to investigate probable adverse health effects of currently marketed Gd-CAs meticulously and to modify the actual approach in using Gd contrast media in daily practice in order to minimize unknown possible health risks. Furthermore, the employment of enhanced wastewater treatment processes that are capable of removing the stable contrast agents, and the evaluation of the ecotoxicity of Gd chelates and human exposure to these emerging contaminants through dermal and ingestion pathways deserve more attention. On the other hand, point source releases of anthropogenic Gd into the aquatic environment presents the opportunity to assess surface water—groundwater interactions and trace the fate of wastewater plume as a proxy for the potential presence of other microcontaminants associated with treated wastewater in freshwater and marine systems.

show abstract

“…Gadolinium deposition in the brain was first reported roughly 3 years ago. Initially, concern was raised regarding gadolinium toxicity in humans, 1 but thus far only a skin rash is evidence of past GBCA administration 51,52 as there have been no reports clearly demonstrating brain toxicity. McDonald et al evaluated the brain tissue collected during the autopsy of patients each administered a total of 420 ml of gadodiamide (linear GBCA) over his or her lifetime but did not find pathological degeneration of brain tissue related to gadolinium deposition.…”

Section: Safetymentioning

confidence: 99%